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INTRODUCTION
Toxoplasma gondii, a protozoan parasite found across the 
world, causes an asymptomatic disease in healthy individuals 
[1,2]. However, immunocompromised conditions in humans, 
such as AIDS and organ transplantation patients, can result in 
acute toxoplasmosis [1]. Recently, T. gondii infection has been 
highlighted to be helpful in some diseases. In this regard, our 
previous study examined the favorable effects of T. gondii infec-
tion and T. gondii lysate antigen (TLA) on neurodegenerative 
diseases and tumor induction [3,4]. In particular, the anti-tu-
morigenic effect of the TLA injection was due to a decrease in 
CD31 for anti-angiogenesis playing a potential role in reduc-
ing the tumor mass [3]. TLA treatment also delayed the tumor 
formation in the early stage of tumor growth in 20-methylcho-
lanthrene-induced tumors [5]. Th1 immune responses gener-
ally play a crucial role in reducing tumor growth in mice in-
fected with T. gondii [6,7]. Accordingly, early cellular events 
causing T-cell immune responses need to be well known 
through animal experiments.
T. gondii infection in a lung carcinoma mouse model shows 
significant increases in CD8+ T cells, IFN-γ mRNA levels, se-
rum IgG2a titers, and cytotoxic T lymphocytes [6]. Apicom-
plexan parasite infections, like T. gondii and malaria, also sug-
gested the importance of Th1 immunity, cytotoxic NK cells, 
and tumor-specific T cells in antitumor effects [8]. In general, 
an antitumor effect in tumor immunotherapy can be devel-
oped through the induction of an adoptive Th1-dominant im-
munity [9,10]. In addition, the immunological memory suit-
able for the generation of tumor-specific cytotoxic T lympho-
cytes is induced when tumor-bearing mice receive Th1 cell 
therapy in the immunomodulating protocol with IL-12 [9,10]. 
IL-12 plays a key role in the interaction between innate and 
adaptive arms of immunity by regulating inflammatory re-
sponses [11]. Endogenous IL-12 is required for resistance to 
many pathogens and chemically induced tumors [11]. In vari-
ous tumor models, IL-12 treatment employs the effector mech-
anism of innate as well as adaptive immunity and develops an 
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Abstract: Toxoplasma gondii is an intracellular protozoan parasite that causes a Th1 cellular immunity. Our previous study 
showed that T. gondii lysate antigen (TLA) treatment in S180 tumor-bearing mice resulted in tumor reduction by suppress-
ing CD31 expression, a marker of angiogenesis. In the present study, to investigate tumor suppressive effect of TLA un-
der the absence of T lymphocytes, athymic nude mice were compared with euthymic mice in the anti-tumorigenic effect 
triggered by TLA in CT26 tumors. According to the results, intratumorally injected TLA reduced tumor growth and TIMP-1 
level, a metastatic marker, in both euthymic and athymic mice. TLA treatment led to a sharp increase in IL-12 expression 
in serum cytokine profiling of athymic mice, and increased MyD88 signals in macrophages derived from the bone mar-
row, implying the activation of innate immunity. The selective induction of IL-12 by TLA treatment had an anti-tumorigenic 
effect.
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antitumor effect in tumor-induced mice [10,11]. Based on these 
findings, the antitumor effect of TLA treatment may be induced 
by some complex mechanisms, such as innate and/or adaptive 
immunity and anti-angiogenesis. In this regard, the present 
study focuses on the immune phenotype related with cytokine 
profiles providing antitumor immune responses after TLA 
treatment, and examines the relationship of T-cells for trigger-
ing of antitumor immunity. For this, the study considers athy-
mic BALB/c/nu/nu mice and compares the results with those 
for euthymic BALB/c mice. The tumor size and cytokine pro-
files of euthymic and athymic mice, and IL-12 induction, its 
down-signals, and myeloid differentiating factor 88 (MyD88) 
in macrophages derived from bone marrow (BMMs) after TLA 
treatment were analyzed to examine the antitumor effect and 
macrophage activation.
MATERIALS AND METHODS 
Experimental animals
Six-week-old female BALB/c mice and BALB/c nu/nu mice 
were purchased from the ORIENT BIO Animal Center (Seong-
nam-si, Korea). All experiments using mice were conducted 
according to the ethical standards of Seoul National Universi-
ty's IACUC (SNU-090102-3). 
Preparation of T. gondii lysate antigen (TLA) 
The TLA was prepared according to the procedures in a pre-
vious study [3]. Pure parasites obtained from mice intraperito-
neally infected with T. gondii RH strain were washed in 10 mM 
PBS (pH 7.4), and sonicated on ice. The supernatant (TLA) 
was filter-sterilized through a membrane with 0.22 μm pores. 
The protein concentration was determined using the BCA™ 
Protein Assay Kit (Thermo Scientific, Rockford, Illinois, USA), 
adjusted by concentration of 100 µg/100 µl, and stored at 
-70°C until used.
Tumor induction
Tumors were generated by subcutaneously injecting 3×106 
CT-26 cells containing EGFP genes inserted into a viral vector 
(a kind gift from Dr. Jung Weon Lee at Department of Phar-
macy, Seoul National University, Seoul, Korea) in the middle 
portion of the dorsal subcutaneous layer of experimental mice. 
CT-26 cells were cultured in complete DMEM containing 10% 
FBS (Invitrogen, Carlsbad, California, USA) and 1% antibiot-
ics (100 IU/ml penicillin G and 100 µg/ml streptomycin) (In-
vitrogen). Because CT-26 cells are stable for expressing the 
EGFP, the intensity of the EGFP after tumor generation can be 
measured by the MaestroTM imaging system (Perkin Elmer 
Corp, Waltham, Massachusetts, USA). 
Measurement of tumor size
The tumor size was measured using a caliper and calculated 
by the following formula: length×width×height×0.5. The tu-
mor weight was measured immediately after mice were sacri-
ficed [3].
Cytokine array
The experimental group was divided into 4 groups; no tu-
mor and tumor induction by PBS and TLA (100 µg/100 µl) 
treatment in both euthymic BABL/c and athymic BABL/c/nu/
nu mice. Pooled sera (n=3) in each group were analyzed using 
a mouse cytokine kit (RayBiotech, Inc., Norcross, Georgia, 
USA) according to the manufacturer's instructions. Signal in-
tensity was quantified using a densitometer (Multi Gauge, Fuji 
Film, Tokyo, Japan), and images were processed using a lumi-
nescent image analyzer (Fuji Film). Data were interpreted by 
comparing the signal intensity of the cytokine level in the no-
tumor group (PBS treatment) with that in the tumor-induc-
tion group (TLA treatment) for each cytokine. The difference 
in the cytokine level was represented in percentage terms. 
Isolation of BMMs
BMMs were prepared as follows [12]. Briefly, the femur and 
tibia of hind legs were removed from sacrificed BALB/c mice 
(8-week old, ORIENT BIO). The cavity of bone marrow was 
flushed with cold complete RPMI media containing 10% FBS 
(Invitrogen) and 1% antibiotics (Invitrogen). Isolated cells 
were washed 3 times with RPMI media and then subcultured 
with the supplementation of L929 cell culture supernatant (as 
a source of the macrophage colony-stimulating factor; M-CSF) 
to be of a 20% concentration [12]. Subcultured cells were incu-
bated for 7 days at 37˚C and 5% CO2 in 6-well culture plates 
(SPL Life Sciences Co., Pocheon, Korea), and adherent cells 
were detached by trypsin (Gibco, Grand Island, New York, 
USA) and used for BMMs. To verify the purity of BMMs, cells 
incubated with M-CSF-conditioned media (L929 cell culture 
supernatant) for 2 weeks were checked with an FITC-conjugat-
ed anti-mouse F4/80 monoclonal antibody (eBioscience, San 
Diego, California, USA). The purity of BMMs exceeded 95%.
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IL-12 induction in BMMs after TLA treatment
The level of IL-12 produced in BMMs with TLA (100 µg/100 
µl) treatment for 24 hr was measured using the sandwich ELI-
SA method. The capture antibody (IL-12) (Mabtech Inc., Nac-
ka Strand, Sweden) was diluted to 2 µg/ml in PBS (pH 7.4), 
coated on a 96-well plate (Costar, New York, USA) at 100 µl/
well, and incubated overnight at 4˚C. After the blocking step, 
the culture supernatant was added to the wells, and incubated 
for 2 hr. Then, a biotin-conjugated anti-IL-12 antibody 
(Mabtech Inc.) was applied and incubated for 1 hr. Finally, 
streptavidin-HRP (Mabtech Inc.) was added and incubated for 
1 hr. TMB solution was used for the enzymatic reaction. OD 
levels at 450 nm were measured using a spectrophotometer 
(Molecular Device, Menlo Park, California, USA). 
Western blot analysis of MyD88 in BMMs treated with 
the TLA
BMMs of 2×105 cells were cultured in 6-well plates (SPL Life 
Sciences Co.), and when their confluency was 90% by obser-
vation of microscopy, the BMMs were treated with the TLA 
(100 µg/100 µl). After 24 hr cultivation, cells were harvested 
and homogenized to collect soluble proteins. The concentra-
tion of soluble proteins was measured using the BCATM Protein 
Assay Kit (Thermo Scientific). Soluble proteins were subjected 
to SDS-PAGE and then transferred to the PVDF membrane. 
The nonspecific binding of the membrane was blocked with 
5% skim milk for 2 hr. Primary antibodies include anti-
MyD88 rabbit IgG (1:5,000, Enzo Life Science, New York, 
USA) and anti-β-actin rabbit IgG (1:10,000, Bethly laboratory 
Inc., Montgomery, Texas, USA). After incubation for 12 hr, 
membranes were washed using 10 mM Tris-buffered saline 
with Tween 20 (TBS-T, pH 7.4), and then HRP-conjugated an-
ti-rabbit IgG (1:20,000, Bethly Inc.) was used as a secondary 
antibody. After incubation for 2 hr, the membrane was colored 
with the ECL chemiluminescence kit (DNR, Jerusalem, Israel). 
Images of the blotted membrane were obtained using the LAS-
1000 lumino-image analyzer (GE Healthcare, Cleveland, 
Ohio, USA). 
Statistical analysis
A statistical analysis was conducted using an unpaired t-test. 
P-values <0.05 were considered significant, and the results are 
presented as the mean±SD.
RESULTS
TLA treatment reduced tumor growth in both euthymic 
(BALB/c) and athymic (BALB/c nu/nu) mice
CT-26 carcinoma cells injected subcutaneously into the mid-
dle portion of the back of mice generated similar-sized tumors 
in both euthymic and athymic mice. Two weeks after the injec-
tion of CT-26 cells, mice were randomly assigned to the PBS- 
and TLA-treated groups. The TLA (100 µg/100 µl) was intro-
duced directly by an intratumoral injection once a day over an 
8-day period. In the PBS-treated group, the tumor size in-
creased steadily over time in both euthymic and athymic mice 
(Fig. 1). Euthymic (Fig. 1A) and athymic (Fig. 1B) mice showed 
a similar trend in terms of the increase in the tumor size. How-
ever, the tumor size in TLA-treated mice did not increase over 
time and was smaller than that in PBS-treated mice. The differ-
ence in the tumor size on day 8 between the PBS- and TLA-
treated groups was larger in athymic mice than in euthymic 
mice with statistical significance. Fig. 1C shows the tumor mass 
isolated from PBS- and TLA-treated athymic mice. The degree 
of metastasis was observed using an imaging system (Fig. 1D). 
According to the results in Fig. 1D, metastasis showed a sharp 
decrease in TLA-treated mice.
A comparison of cytokine profiles between euthymic and 
athymic tumor-bearing mice
Sera collected on day 8 (the end of the experiment) were 
pooled and applied to an assay to investigate cytokine profiles. 
Serum cytokine profiles of the PBS- and TLA-treated euthymic 
and athymic BALB/c/nu/nu mice were compared with those of 
non-tumor BALB/c and BABL/c/nu/nu mice based on the sig-
nal intensity of each cytokine (Fig. 2A, B). The overall pattern 
of the relative signal value (%) was as follows: Tumor induc-
tion (PBS treatment) in euthymic mice showed an increase be-
low 50% at most cytokine levels except for TIMP-1, a tumor 
marker, in comparison to that in non-tumor mice (Fig. 2A). 
Tumor induction in athymic mice (PBS treatment) led to im-
mune suppression to about -50% at most cytokine levels ex-
cept for TIMP-1 in comparison to that in non-tumor athymic 
mice. TLA treatment in both euthymic and athymic mice in-
duced a slight increase within 50% at most cytokine levels ex-
cept for IL-12p40 and TIMP-1, suggesting an increase in im-
munity by TLA treatment (Fig. 2A, B). In particular, a clear out-
come of TLA treatment is the sharp IL-12 induction in athymic 
mice. The results showing a decrease in TIMP-1 from 70.1% to 
608  Korean J Parasitol Vol. 52, No. 6: 605-612, December 2014
33.4% in euthymic mice and from 401.8% to 90.0% in athy-
mic mice indicates a reduction in tumor growth and metasta-
sis by TLA treatment. This is consistent with the results for the 
tumor size and metastasis based on real images in Fig. 1C and 
1D and demonstrates that IL-12, which showed increases in 
cytokine expression in both euthymic and athymic mice, had 
a significant anti-tumorigenic effect. 
Prominent IL-12 induction as a unique function of TLA
Athymic mice deprived of mature T lymphocytes showed a 
marked increase in IL-12 by TLA treatment in a tumor-bearing 
state (Fig. 2B). To investigate whether prominent IL-12 pro-
duction would be induced after TLA treatment regardless of 
the tumor status, PBS or TLA treatment was provided to tumor 
and non-tumor mice (Fig. 3). According to the results, IL-12 
Fig. 1. Effects of TLA treatment on CT26 tumor growth. When the tumor mass was about 40 mm3, mice were given PBS or TLA 
through an intratumoral injection in euthymic (A, n=6) and athymic (B, n=8) tumor groups. In athymic mice (B), tumor growth in TLA-
treated mice was significantly lower from day 6 after TLA treatment than that in PBS-treated mice (*P<0.05). Images of tumors isolated 
in athymic mice on day 8 of an intratumoral injection with PBS or the TLA are shown (C). Because the EGFP gene was stably expressed 
in CT26 cells, the metastasis of inoculated CT26 cells was observed using an imaging system (D). 
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was produced directly by TLA treatment regardless of the tu-
mor status. Relative IL-12 expression (e.g., the level of expres-
sion relative to the IL-12 level in non-tumor and PBS-treated 
mice) increased through TLA treatment by about 320-400% 
regardless of the presence of a tumor (Fig. 3). This indicates 
that the treatment of TLA alone induced IL-12 production. 
Increase of IL-12 and MyD88 cell signal induced by TLA 
treatment in BMMs
For athymic mice, TLA treatment directly induced IL-12 pro-
duction (Figs. 2, 3). This suggests that a major candidate cell 
population for IL-12 production under the deprivation of ma-
ture T cells may be macrophages. Accordingly, BMMs were 
used to examine the relationship between TLA treatment and 
IL-12 expression (Fig. 4). BMMs, 2×105 cells, were loaded 
onto a well of a 96-well plate and cultured under 3 TLA con-
centrations (0, 5, and 10 µg/ml). BMMs incubated with the 
TLA for 24 hr were examined on the concentration of IL-
12p40 (Fig. 4). The expression of IL-12p40 was increased with 
an increase in the TLA concentration (Fig. 4A). As a down sig-
nal of IL-12 production in BMMs, changes in MyD88 expres-
sion were verified through a western blot analysis. The expres-
sion of MyD88 was increased with an increase in the TLA con-
centration (Fig. 4B). As a result, the change of MyD88 signals 
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comparison to that in non-tumor euthymic (A) and athy-
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under the TLA treatment was consistent with the result for IL-
12 expression.
DISCUSSION
Recent studies have provided potential therapeutic results 
underlying tumor growth reductions immunologically regu-
lated by microorganisms [3,5-8,13-15]. In particular, bacteria 
and viruses show anti-tumorigenesis by mechanisms with cy-
tolytic activity through their intracellular replication [13,14]. 
Besides, the anti-tumorigenic effect of T. gondii has been veri-
fied in several in vivo and in vitro experiments [3,5-8]. For ex-
ample, there is a decrease in CD31, a marker for angiogenesis, 
after an intratumoral injection of TLA, suggesting some molec-
ular intervention in anti-angiogenesis [3]. T. gondii infection 
triggers a Th1 cellular immune response for the inhibition of 
angiogenesis [6]. Because a therapeutic measure for the inhibi-
tion of tumors may be induced by Th1-dominant immunity 
[9], the antitumor effect of T. gondii infection reported in vari-
ous tumors, including sarcomas, lung carcinoma, and ependy-
moblastomas, was also expected by cellular immune responses 
triggered by T. gondii [3,6,7]. 
Our previous study reported that T. gondii infection as well 
as TLA treatment showed a similar anti-tumorigenic effect sug-
gesting that the immune environment elicited by TLA is simi-
lar to that by T. gondii infection. Accordingly, the present study 
addressed the topic of early triggering mechanisms underlying 
the antitumor effect of TLA treatment, such as early innate or 
adaptive immune responses. For this, the immune characteris-
tics of euthymic BALB/c mice were compared with those of 
athymic nu/nu BALB/c mice. EGFP-inserted CT-26 cells were 
subcutaneously injected into mice to induce a tumor mass. 
The results after an intratumoral injection of PBS or the TLA 
indicate that the tumor size was smaller in TLA-treated mice 
than in PBS-treated mice, and this pattern was similar between 
euthymic (BALB/c) and athymic (BALB/c nu/nu) mice with a 
significant difference in athymic mice. Our data shows that the 
TLA has anti-tumorigenic effect regardless of the type of tumor, 
such as S180 sarcoma and CT26 colon carcinoma, and with-
out engaging T cells. Another important finding is that, accord-
ing to image data on EGFP fluorescence intensity and cytokine 
profiling data, TLA treatment clearly reduced the metastasis of 
locally introduced tumor cells and serum TIMP-1 level, a met-
astatic marker. Tissue inhibitor of metalloproteinase-1 (TIMP-
1) has been suggested as a marker for both the treatment prog-
nosis and therapeutic responses and was clinically demon-
strated in breast cancer [16]. In the present study, the TIMP-1 
level showed a marked increase in the tumor-induced state in 
both euthymic and athymic mice (70.1% and 401.8%, respec-
tively) in comparison to non-tumor mice. After TLA treatment, 
however, the TIMP-1 level decreased sharply to 33.4% and 
90.0%, respectively, suggesting metastasis suppression. 
As mentioned earlier, Th1-type immune responses triggered 
by microorganisms (some types of viruses, bacteria, and para-
sites) are partially similar to antitumor immune mechanisms 
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[3,5-8]. The key role played by Th1-dominant immunity in tu-
mor immunology has been well documented for IL-12, NK 
cells, and other Th1 cytokines, and the induction of these cyto-
kines has been based on the development of tumor-specific 
immunotherapy [9]. In this respect, T. gondii infection can se-
lectively produce IL-12, which is also important in tumor im-
munology [17], and this raises the question of the extent to 
which the antitumor effect of TLA treatment depends on T 
cells. However, because our results showed the reduction of tu-
mor mass under the state of a sharp increase of IL-12 and de-
privation of mature T cells, this study highlights that IL-12 in-
duced by TLA treatment plays the important role in the induc-
tion of anti-tumorigenic effects. 
In general, an increase in IL-12, CD8+ T-cells, IFN-γ, serum 
IgG2a, or NK cells suggests an increase in the Th1 immune re-
sponse and indicates the induction of antitumor effects [6,9, 
11,18,19]. Although IL-12 induction has an anti-tumorigenic 
effect through early innate immune responses, further cellular 
immunity is essential for some immune synergy in the reduc-
tion of tumor growth. However, other proinflammatory cyto-
kines except for IL-12 (IL-12p40) showed no remarkable in-
creases in athymic nude mice. In general, NK cells are a major 
producer of IFN-γ, which is related to an IL-12-induced antitu-
mor effect [19]. The increase in IL-12 observed in the present 
study may be linked to further cellular immunity in both eu-
thymic and athymic mice. Because nude mice show the ap-
pearance of marked granulocytosis instead of lymphocytes 
[20], our results strongly suggest that the antitumor effect of 
TLA treatment is related to not T-cell immunity but enforced 
innate immunity.
To examine whether TLA treatment initiates innate immuni-
ty by macrophages, this study considered BMMs and investi-
gated the increase of TLR signaling in macrophage activation. 
Macrophages and NK cells are major immune cells against tu-
mors, and their antitumor immunity depends on IL-12 pro-
duction and cell activation [21]. During an innate immune re-
sponse, the activation of macrophages can be determined by 
TLR signaling through MyD88 [11,22,23]. TLA treatment in-
duced IL-12 production in BMMs, which is consistent with the 
results for euthymic and athymic mice. In addition, MyD88 
signals were increased in a dose-dependent manner with the 
TLA concentration. MyD88-triggering IL-12 synthesis results 
from the stimulation of the Toll-like receptors (TLR) [11,17, 
22]. Recent studies have identified some proteins that selec-
tively induce IL-12 production from T. gondii [24-27]. Among 
these, profilin triggers MyD88 signaling [24,25]. Although the 
present study does not investigates the role of profilin in IL-12 
production after TLA treatment, the results suggest that a cer-
tain TLA component, like T. gondii profilin, may induce resis-
tance to tumor growth through mechanisms related to early 
and selective IL-12 induction. 
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